H
Hiroto Inaba
Researcher at St. Jude Children's Research Hospital
Publications - 169
Citations - 6131
Hiroto Inaba is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Medicine & Leukemia. The author has an hindex of 38, co-authored 138 publications receiving 4557 citations. Previous affiliations of Hiroto Inaba include Boston Children's Hospital & University of Tennessee Health Science Center.
Papers
More filters
Journal ArticleDOI
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz,Hiroto Inaba,Raul C. Ribeiro,Stanley Pounds,Barbara Rooney,Teresa M. Bell,Ching-Hon Pui,Wing Leung +7 more
TL;DR: Low-dose immunosuppression followed by donor-recipient inhibitory KIR-HLA mismatched NK cells is well tolerated by patients and results in successful engraftment, and is proposed in a phase II trial to decrease relapse without increasing mortality in children with AML.
Journal ArticleDOI
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
Takaya Moriyama,Takaya Moriyama,Rina Nishii,Rina Nishii,Virginia Perez-Andreu,Wenjian Yang,Federico Antillon Klussmann,Xujie Zhao,Ting-Nien Lin,Keito Hoshitsuki,Keito Hoshitsuki,Jacob Nersting,Kentaro Kihira,Ute Hofmann,Yoshihiro Komada,Motohiro Kato,Robert McCorkle,Lie Li,Katsuyoshi Koh,Cesar R. Najera,Shirley Kow-Yin Kham,Tomoya Isobe,Zhiwei Chen,Edwynn Kean Hui Chiew,Deepa Bhojwani,Cynthia Jeffries,Yan Lu,Matthias Schwab,Hiroto Inaba,Ching-Hon Pui,Mary V. Relling,Atsushi Manabe,Hiroki Hori,Kjeld Schmiegelow,Kjeld Schmiegelow,Allen Eng Juh Yeoh,Allen Eng Juh Yeoh,William E. Evans,Jun J. Yang +38 more
TL;DR: Results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may inform personalized thiopurine therapy, and patients with defective N UDT15 alleles showed excessive levels of thiopURine active metabolites and toxicity.
Journal ArticleDOI
Glucocorticoid use in acute lymphoblastic leukaemia
TL;DR: In this paper, the optimal dose and bioequivalence of prednisone and dexamethasone for the treatment of acute lymphoblastic leukaemia (ALL) was established.
Journal ArticleDOI
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Thomas B. Alexander,Thomas B. Alexander,Zhaohui Gu,Ilaria Iacobucci,Kirsten Dickerson,John K. Choi,Beisi Xu,Debbie Payne-Turner,Hiroki Yoshihara,Mignon L. Loh,John T. Horan,Barbara Buldini,Giuseppe Basso,Sarah Elitzur,Valerie de Haas,C. Michel Zwaan,Allen Eng Juh Yeoh,Dirk Reinhardt,Daisuke Tomizawa,Nobutaka Kiyokawa,Tim Lammens,Barbara De Moerloose,Daniel Catchpoole,Hiroki Hori,Anthony V. Moorman,Andrew S. Moore,Ondrej Hrusak,Soheil Meshinchi,Soheil Meshinchi,Etan Orgel,Meenakshi Devidas,Michael J. Borowitz,Brent L. Wood,Nyla A. Heerema,Andrew Carrol,Yung-Li Yang,Malcolm A. Smith,Tanja M. Davidsen,Leandro C. Hermida,Patee Gesuwan,Marco A. Marra,Yussanne Ma,Andrew J. Mungall,Richard A. Moore,Steven J.M. Jones,Marcus B. Valentine,Laura J. Janke,Jeffrey E. Rubnitz,Ching-Hon Pui,Liang Ding,Yu Liu,Jinghui Zhang,Kim E. Nichols,James R. Downing,Xueyuan Cao,Lei Shi,Stanley Pounds,Scott Newman,Deqing Pei,Jaime M. Guidry Auvil,Daniela S. Gerhard,Stephen P. Hunger,Hiroto Inaba,Charles G. Mullighan +63 more
TL;DR: A large-scale genomics study shows that the cell of origin and founding mutations determine disease subtype and lead to the expression of multiple haematopoietic lineage-defining antigens in mixed phenotype acute leukaemia.
Journal ArticleDOI
Pediatric acute lymphoblastic leukemia.
TL;DR: This review describes key advances in the understanding of the biology of ALL and optimal approaches to risk-stratification and therapy, and it suggests key areas for basic and clinical research.